Biomea Fusion, Inc. (BMEA): R&D Expense
$61.98M
Year ended 2025-12-31
$40.78M
Trailing 12 months to 2026-06-30
-0.4%
3-year compound annual growth
+76.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.98M | -47.5% | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | $118.08M | +15.2% | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | $102.55M | +63.5% | 2026-03-24, From 2023-01-01 |
| 2022-12-31 | $62.71M | +124.0% | 2025-03-31, From 2022-01-01 |
| 2021-12-31 | $28.00M | +662.6% | 2024-03-28, From 2021-01-01 |
| 2020-12-31 | $3.67M | +236.2% | 2023-03-28, From 2020-01-01 |
| 2019-12-31 | $1.09M | n/a | 2022-02-28, From 2019-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | 2025-12-31 | $61.98M | -47.5% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| Scynexis Inc (SCYX) | 2025-12-31 | $22.28M | -15.6% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $77.00M | -33.8% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $22.84M | +180.2% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $107.0K | -82.0% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $0 | -100.0% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $7.98M | +10.9% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $28.53M | -50.4% |
Compare BMEA, RANI, SCYX, ALXO side by side · Screen every company in Pharmaceutical Preparations ↗